Evidence map›Paper›PMID 27058463›Full record

ArticleBiopreservation and biobanking2016

Realizing Our Potential in Biobanking: Disease Advocacy Organizations Enliven Translational Research.

Kelly A Edwards, Sharon F Terry, Dana Gold, Elizabeth J Horn, Mary Schwartz, Molly Stuart, Suzanne D Vernon

Abstract read
In one paragraph

Article in Biopreservation and biobanking, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kelly A Edwards1 Department of Bioethics and Humanities, University of Washington School of Medicine , Seattle, Washington.
Sharon F Terry2 Genetic Alliance, Inc. , Washington, District of Columbia.
Dana Gold4 University of Washington , Seattle, Washington.
Elizabeth J Horn5 LHC BioSolutions, Portland, Oregon.
Mary Schwartz6 Pachyonychia Congenita Project, Salt Lake City, Utah.
Molly Stuart7 Strategic Change Consultant, Davis, California.
Suzanne D Vernon8 CFIDS Association of America, Charlotte, North Carolina.
University of Washington · USPachyonychia Congenita Project · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biobanks are increasingly powerful tools used in translational research, and disease advocacy organizations (DAOs) are making their presence known as research drivers and partners. We examined DAO approaches to biobanking to inform how the enterprise of biobanking can grow and become even more impactful in human health. In this commentary, we outline overarching approaches from successful DAO biobanks. These lessons learned suggest principles that can create a more participant-centric approach and illustrate the key roles DAOs can play as partners in research initiatives. DAO approaches to biobanking for translational research include the following: be outcome driven; forge alliances that are unexpected-build bridges to enhance translation; come ready for success; be nimble, flexible, and adaptable; and remember that people matter. Each of these principles led to particular practices that have increased the translational impact of biobank collections. The research practices discussed can inform partnerships in all sectors going forward.

Indexed as

Biological Specimen BanksHumansSpecimen HandlingTranslational Research, Biomedical

Identifiers

PMID27058463
PMCPMC4991568
OpenAlexW2404222898

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.